top of page

About Us

Adcytherix is a biopharmaceutical company focused on the development of novel antibody drug conjugates (ADC) to treat high unmet need diseases such as cancer.

The company is led by a seasoned management team and is supported by a network of world-leading experts in the field of ADC development.


Adcytherix is backed by a syndicate of leading life science investors including Pontifax, Pureos Bioventures, RA Capital Management and Dawn Biopharma (a platform controlled by KKR).


Adcytherix is based in Marseille, France.

Management Team

Jack Elands

CEO and company founder

Dr. Jack Elands is founder and former CEO of Emergence Therapeutics, Talix Therapeutics, CEO of BliNK Biomedical and CEO and co-founder of Amakem, CEO of Vitec, co-founder of MImAbs

Carsten Dehning

CFO and co-founder

Carsten Dehning is former CFO and co-founder of Emergence Therapeutics, former CFO, CEO and senior advisor of various companies and investors in the healthcare sector

Xavier Preville

VP, Head of Research & Pre-Clinical Development and co-founder

Dr. Xavier Preville is co-founder and former CSO of Emergence Therapeutics, former CSO at Talix Therapeutics, director of preclinical development at Transgene and BT Pharma (Genticel)

Thierry Menguy

Senior Director, Head of CMC operations

Dr. Thierry Menguy is the former head of CMC at LinKinVax, CTO and co-founder at ElsaLys Biotech. He has also held senior positions in CMC and R&D of large molecules at Transgene, Biométhodes and Genodyssee

Supervisory Committee

Ran Nussbaum

Managing Partner at Pontifax Venture Capital

Ohad Hammer

Partner at Pontifax Venture Capital

Ximing Ding

Investment Manager at Pureos Bioventures

Iyona Rajkomar

Managing Partner at Dawn Biopharma (a platform controlled by KKR)

Matthew Hammond

Principal at RA Capital Management

bottom of page